Expertos Invitados




Artículos relacionadosArtículos relacionadosArtículos relacionados
Artículos afines de siicsalud publicados en los últimos 4 meses
ABORDAJE TERAPÉUTICO Y ASISTENCIAL DEL PACIENTE ONCOLÓGICO CON PSORIASIS
Actas Dermo-Sifiliográficas :1-10
Difundido en siicsalud: 27 sep 2024
INFLUENCIA DE LA PSORIASIS EN LA PLANIFICACIÓN FAMILIAR
Actas Dermo-Sifiliográficas 115(1):10-20
Difundido en siicsalud: 12 ago 2024

UTILIDAD DEL CALCIPOTRIOL EN DERMATOLOGIA

(especial para SIIC © Derechos reservados)
Esta revisión de trabajos acerca de los usos clínicos del calcipotriol tópico muestra su utilidad en muchos trastornos dérmicos, lo que indica el gran potencial que ofrecen los análogos de la vitamina D3.
holm9.jpg Autor:
Elisabeth Holm,
Columnista Experto de SIIC

Institución:
Division of Dermatology Department of Medicine Roskilde Hospital Roskilde, Denmark

Artículos publicados por Elisabeth Holm,
Coautor
Gregor BE Jemec* 
MD, DmedSci. Division of dermatology, department of Medicine, Roskilde Hospital*
Recepción del artículo
22 de Marzo, 2004 		Aprobación
21 de Abril, 2004
Primera edición
15 de Febrero, 2005 		Segunda edición, ampliada y corregida
7 de Junio, 2021

UTILIDAD DEL CALCIPOTRIOL EN DERMATOLOGIA

Resumen
Antecedentes: El calcipotriol (calcipotrieno) es un análogo de la vitamina D3, con efectos antiproliferativos y antiinflamatorios, que estimula la diferenciación terminal. En Europa se lo emplea en el tratamiento de la psoriasis vulgar desde 1991 y en EE.UU. desde 1994. Objetivo: El objetivo de esta revisión es ofrecer una actualización acerca de las potenciales aplicaciones clínicas del tratamiento con calcipotriol tópico para otras enfermedades, además de la psoriasis. Métodos: Revisión de la bibliografía existente que describe los estudios clínicos de calcipotriol en el período de 2000 a 2004. Resultados: Se encontraron en total 51 artículos originales que nombraban 26 enfermedades diferentes en las que se describía el uso clínico del ungüento de calcipotriol. Los artículos fueron principalmente informes de casos (n = 33) y estudios de observación (n = 12), pero 6 de ellos describieron pequeños ensayos controlados aleatorizados. Catorce de las 26 diferentes enfermedades no fueron descritas en revisiones previas. Conclusión: El calcipotriol generalmente es efectivo en enfermedades caracterizadas por elementos patogénicos como deterioro en la diferenciación o aumento de la proliferación de queratinocitos y lifocitos T activados. Esta revisión de la bibliografía sugiere que los estudios aleatorizados, a doble ciego, controlados con placebo, del tratamiento con calcipotriol pueden ser útiles en varias enfermedades.

Palabras clave
Calcipotriol, tratamiento con calcipotrieno, psoriasis


Artículo completo
(castellano)
Extensión:  +/-7.79 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

CALCIPOTRIOL. THE SPECTRUM OF CLINICAL EXPERIENCE OF A DECADE

Abstract
Background: Calcipotriol (calcipotriene) is a vitamin D3-analogue, which has anti-proliferative and anti-inflammatory effect, and stimulates terminal differentiation. It has been an established treatment of psoriasis vulgaris since 1991 in Europe and 1994 in USA. Objective: The aim of this review was to give an update upon the potential clinical applications of topical calcipotriol treatment for other diseases than psoriasis. Methods: Review of the existing literature describing clinical studies of calcipotriol in the period from 2000 to 2004. Results: A total of 51 original papers were found describing 26 different diseases where the clinical use of calcipotriol ointment was described. These papers were predominantly case reports (n = 33) and observational studies (n = 12), but 6 papers described small-randomised controlled trials. 14 out of the 26 different diseases have not been described in previous reviews. Conclusion: Calcipotriol may generally be effective in diseases characterised by pathogenic elements such as impaired differentiation or increased keratinocytes proliferation, and activated T-lymphocytes. This review of the existing literature suggests that randomised, double blind, placebo-controlled studies of calcipotriol therapy may be worthwhile in a number of diseases.

Key words
Calcipotriol, calcipotriene treatment, not psoriasis


Full text
(english)
 para suscriptores/ assinantes
Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Dermatología, Oncología
Relacionadas: Farmacología, Hematología



Comprar este artículo
Extensión: 7.79 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Bibliografía del artículo
  1. Masood R, Nagpal S, Zheng T, Cai J, Tulpule A, Smith DL et al. Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood 2000; 96(9):3188-3194.
  2. Kragballe K, Steijlen PM, Ibsen HH, van de Kerkhof PC, Esmann J, Sorensen LH et al. Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization. Results of a randomized, double-blind, vehicle-controlled, right/left comparative study. Arch Dermatol 1995; 131(5):556-560.
  3. Holm EA, Jemec GB. The therapeutic potential of calcipotriol in diseases other than psoriasis. Int J Dermatol 2002; 41(1):38-43.
  4. Parish JL. Topical vitamin D3 analogues: unapproved uses, dosages, or indications. Clin Dermatol 2002; 20(5):558-562.
  5. Gupta AK, Browne M, Bluhm R. Nonpsoriatic uses of calcipotriol. J Cutan Med Surg 2002; 6(5):442-448.
  6. Hermanns-Le T, Hermanns JF, Pierard GE. Juvenile acanthosis nigricans and insulin resistance. Pediatr Dermatol 2002; 19(1):12-14.
  7. Cruz PD, Jr., Hud JA, Jr. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol 1992; 98(6 Suppl):82S-85S.
  8. Contreras ME, Gottfried LC, Bang RH, Palmer CH. Axillary intertriginous granular parakeratosis responsive to topical calcipotriene and ammonium lactate. Int J Dermatol 2003; 42(5):382-383.
  9. Metze D, Rutten A. Granular parakeratosis - a unique acquired disorder of keratinization. J Cutan Pathol 1999; 26(7):339-352.
  10. Mehregan DA, Thomas JE, Mehregan DR. Intertriginous granular parakeratosis. J Am Acad Dermatol 1998; 39(3):495-496.
  11. Bogenrieder T, Landthaler M, Stolz W. Bullous congenital ichthyosiform erythroderma: safe and effective topical treatment with calcipotriol ointment in a child. Acta Derm Venereol 2003; 83(1):52-54.
  12. Boffa MJ. Erosive pustular dermatosis of the scalp successfully treated with calcipotriol cream. Br J Dermatol 2003; 148(3):593-595.
  13. Bayramgurler D, Apaydin R, Dokmeci S, Ustun M. Flegel's disease: treatment with topical calcipotriol. Clin Exp Dermatol 2002; 27(2):161-162.
  14. Metze D, Lubke D, Luger T. [Hyperkeratosis lenticularis perstans (Flegel's disease) - a complex disorder of epidermal differentiation with good response to a synthetic vitamin D3 derivate]. Hautarzt 2000; 51(1):31-35.
  15. Blaheta HJ, Metzler G, Rassner G, Garbe C. Hyperkeratosis lenticularis perstans (Flegel's disease)--lack of response to treatment with tacalcitol and calcipotriol. Dermatology 2001; 202(3):255-258.
  16. Bayramgurler D, Apaydin R, Bilen N. Limited benefit of topical calcipotriol in lichen planus treatment: a preliminary study. J Dermatolog Treat 2002; 13(3):129-132.
  17. Kreuter A, Gambichler T, Sauermann K, Jansen T, Altmeyer P, Hoffmann K. Extragenital lichen sclerosus successfully treated with topical calcipotriol: evaluation by in vivo confocal laser scanning microscopy. Br J Dermatol 2002; 146(2):332-333.
  18. Gambichler T, Kreuter A, Rotterdam S, Altmeyer P, Hoffmann K. Linear scleroderma 'en coup de sabre' treated with topical calcipotriol and cream psoralen plus ultraviolet A. J Eur Acad Dermatol Venereol 2003; 17(5):601-602.
  19. Kowalzick L, Suckow S, Moertel J, Mischke J, Waldmann T, Poennighaus J et al. Localized scleroderma en coup de sabre: Succesfultreatment with topical calcipotriol and medium-dose UVA-1 phototherapy. Aktuelle Dermatologie 2002; 28(6):193-195.
  20. Bayramgurler D, Bilen N, Apaydin R, Ercin C. Nevoid hyperkeratosis of the nipple and areola: treatment of two patients with topical calcipotriol. J Am Acad Dermatol 2002; 46(1):131-133.
  21. Femiano F, Gombos F, Scully C, Battista C, Belnome G, Esposito V. Oral leukoplakia: open trial of topical therapy with calcipotriol compared with tretinoin. Int J Oral Maxillofac Surg 2001; 30(5):402-406.
  22. De Rie MA, Di Nuzzo S, Brands S, Hansen AB, Bos JD. Calcipotriol ointment and cream or their vehicles applied immediately before irradiation inhibit ultraviolet B-induced erythema. Br J Dermatol 2000; 142(6):1160-1165.
  23. Ameen M, Exarchou V, Chu AC. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol 2001; 145(3):476-479.
  24. Dogra S, Parsad D. Combination of narrowband UV-B and topical calcipotriene in vitiligo. Arch Dermatol 2003; 139(3):393.
  25. Ermis O, Alpsoy E, Cetin L, Yilmaz E. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol A placebo-controlled double-blind study. Br J Dermatol 2001; 145(3):472-475.
  26. Kose O, Riza GA, Kurumlu Z, Erol E. Calcipotriol ointment versus clobetasol ointment in localized vitiligo: an open, comparative clinical trial. Int J Dermatol 2002; 41(9):616-618.
  27. Parsad D, Kanwar AJ, Kumar B. SP-20 Repigmentation Patterns and their Co-Relation with Different Treatment Modalities, Speed and Stability of pigmentation in 352 Vitiliginous Patches. Pigment Cell Res 2003; 16(5):587.
  28. Uksal U, Borlu M, Atasavun C, Ferahbas A. Comparison of four treatment regimens for vitiligo in children. European Journal of Pediatric Dermatology 2002; 12(4):231-234.
  29. Yalcin B, Sahin S, Bukulmez G, Karaduman A, Atakan N, Akan T et al. Experience with calcipotriol as adjunctive treatment for vitiligo in patients who do not respond to PUVA alone: a preliminary study. J Am Acad Dermatol 2001; 44(4):634-637.
  30. Baysal V, Yildirim M, Erel A, Kesici D. Is the combination of calcipotriol and PUVA effective in vitiligo J Eur Acad Dermatol Venereol 2003; 17(3):299-302.
  31. Chiaverini C, Passeron T, Ortonne JP. Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol 2002; 16(2):137-138.
  32. Kokelj F, Plozzer C, Trevisan G. Uselessness of topical calcipotriol as monotherapy for acrodermatitis continua of Hallopeau. Acta Derm Venereol 2001; 81(2):153.
  33. Smit JV, Cox S, Blokx WA, van de Kerhof PC, de Jongh GJ, de Jong EM. Actinic keratoses in renal transplant recipients do not improve with calcipotriol cream and all-trans retinoic acid cream as monotherapies or in combination during a 6-week treatment period. Br J Dermatol 2002; 147(4):816-818.
  34. Blaheta HJ, Metzler G, Rassner G, Garbe C. Hyperkeratosis lenticularis perstans (Flegel's disease)--lack of response to treatment with tacalcitol and calcipotriol. Dermatology 2001; 202(3):255-258.
  35. Jayaraman AG, Pomerantz D, Robinson-Bostom L. Keratosis lichenoides chronica mimicking verrucous secondary syphilis. J Am Acad Dermatol 2003; 49(3):511-513.
  36. Taberner R, Puig L, Fernandez-Figueras T, Alomar A. Keratosis lichenoides chronica. J Eur Acad Dermatol Venereol 2001; 15(1):84-85.
  37. Moreno M, Torrelo A, Mediero I, Zambrano A. Extragenital lichen sclerosus et atrophicus in children. Actas dermo sifiliograficas 2000; 91(9):385-389.
  38. Ling TC, Herrick AL, Andrew SM, Brammah T, Griffiths CE. Keloidal scleroderma. Clin Exp Dermatol 2003; 28(2):171-173.
  39. Mehta RK, Burrows NP, Payne CM, Mendelsohn SS, Pope FM, Rytina E. Elastosis perforans serpiginosa and associated disorders. Clin Exp Dermatol 2001; 26(6):521-524.
  40. Bohm M, Luger TA, Metze D. [Acanthosis nigricans associated with transitional cell carcinoma of the bladder--symptomatic treatment with calcipotriol]. Hautarzt 1999; 50(8):593-596.
  41. Kuijpers AL, Dooren-Greebe RJ, van de Kerkhof PC. Acrodermatitis continua of Hallopeau: response to combined treatment with acitretin and calcipotriol ointment. Dermatology 1996; 192(4):357-359.
  42. Kurkcuoglu N, Celebi CR. Confluent and reticulated papillomatosis: response to topical calcipotriol. Dermatology 1995; 191(4):341-342.
  43. Bower M, Colston KW, Stein RC, Hedley A, Gazet JC, Ford HT et al. Topical calcipotriol treatment in advanced breast cancer. Lancet 1991; 337(8743):701-702.
  44. Harrison PV, Stollery N. Disseminated superficial actinic porokeratosis responding to calcipotriol. Clin Exp Dermatol 1994; 19(1):95.
  45. Lucker GP, van de Kerkhof PC, Steijlen PM. Topical calcipotriol in the treatment of epidermolytic palmoplantar keratoderma of Vorner. Br J Dermatol 1994; 130(4):543-545.
  46. Gniadecki R. Calcipotriol for erythema annulare centrifugum. Br J Dermatol 2002; 146(2):317-319.
  47. Keohane SG, Cork MJ. Treatment of Grover's disease with calcipotriol (Dovonex). Br J Dermatol 1995; 132(5):832-833.
  48. Lucker GP, van de Kerkhof PC, van Dijk MR, Steijlen PM. Effect of topical calcipotriol on congenital ichthyoses. Br J Dermatol 1994; 131(4):546-550.
  49. Gatti S, Carrozzo AM, Orlandi A, Nini G. Treatment of inflammatory linear verrucous epidermal naevus with calcipotriol. Br J Dermatol 1995; 132(5):837-839.
  50. Grunwald MH, Hallel-Halevy D, Amichai B. Keratosis lichenoides chronica: response to topical calcipotriol. J Am Acad Dermatol 1997; 37(2 Pt 1):263-264.
  51. Khoo BP, Tay YK, Goh CL. Calcipotriol ointment vs. betamethasone 17-valerate ointment in the treatment of lichen amyloidosis. Int J Dermatol 1999; 38(7):539-541.
  52. Koeger A, Rozenberg S, Fautrel B. Effectiveness of topical calcitriol for Localized Scleroderma. The Journal of Rheumatology 1999; 26(1):239-240.
  53. Korge B, Bonnekoh B. Morbus Reiter, Ansprechen auf Calcipotriol. Der Hautarzt 1994; 69(8):566-568.
  54. Cunningham BB, Landells ID, Langman C, Sailer DE, Paller AS. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 1998; 39(2 Pt 1):211-215.
  55. Tosti A, Piraccini BM, Cameli N, Kokely F, Plozzer C, Cannata GE et al. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998; 139(4):655-659.
  56. Bayramgurler D, Bilen N, Apaydin R, Ercin C. Nevoid hyperkeratosis of the nipple and areola: treatment of two patients with topical calcipotriol. J Am Acad Dermatol 2002; 46(1):131-133.
  57. Van de Kerkhof PC, Steijlen PM. Topical treatment of pityriasis rubra pilaris with calcipotriol. Br J Dermatol 1994; 130(5):675-678.
  58. Wong SS, Goh CL. Double-blind, right/left comparison of calcipotriol ointment and betamethasone ointment in the treatment of Prurigo nodularis. Arch Dermatol 2000; 136(6):807-808.
  59. Kowalzick L, Schlehaider U. An open pilot study of topical calcipotriol in seborrhoeic eczema. Journal of Dermatological Treatment 1998; 9:49-51.
  60. Lucker GP, van de Kerkhof PC, Cruysberg JR, der Kinderen DJ, Steijlen PM. Topical treatment of Sjogren-Larsson syndrome with calcipotriol. Dermatology 1995; 190(4):292-294.
  61. Scott-Mackie P, Hickish T, Mortimer P, Sloane J, Cunningham D. Calcipotriol and regression in T-cell lymphoma of skin. Lancet 1993; 342(8864):172.
  62. Parsad D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology 1998; 197(2):167-170.
Título español
Resumen
 Palabras clave
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

 English title
 Abstract
 Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia

Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008